latest news releases from the newsroom
Optio Software, Inc.
QAD Inc. and Optio Software Expand Worldwide Alliance
ALPHARETTA, Ga., Oct. 26, 2004 (PRIMEZONE) -- Optio(r) Software (OTCBB:OPTO), a leading provider of document output management and forms automation solutions, today announces that QAD(tm) Inc., (Nasdaq:QADI) has added Optio e.ComIntegrate(tm) and DesignStudio(tm) to its worldwide Solution Center, an information portal used by the global QAD sales force. QAD sales consultants will use these Optio products to demonstrate how customers and prospects can add value to MFG/PRO(r) eB2 enterprise software.
Talking Stocks Issues Favorable Report on FinancialContent, Inc.
DALLAS, Oct. 26, 2004 (PRIMEZONE) -- Jeff Bishop, Senior Investment Analyst for TalkingStocks.com, a leading online destination for small-cap investors, has issued a favorable report on FinancialContent, Inc. (OTCBB:FCON). In the report, Mr. Bishop offers the rating of 'Long Term Attractive.' From today's report, Mr. Bishop summarizes some of the rationale: "We feel that FinancialContent represents a solid investment at current levels. Though the headline number of 130% revenue increase got the attention of many investors, it was quickly discounted due to the fact that a bulk of this gain was attributable to a one-time client acquisition. Investors who chose to dig a little deeper into the financial statements will realize that company's growth apart from the one-time gain was still quite remarkable -- over 40% internal growth."
Biovitrum AB and Pharmacopeia Form Strategic Research Alliance
STOCKHOLM, Sweden and PRINCETON, N.J., Oct. 26, 2004 (PRIMEZONE) -- Biovitrum AB and Pharmacopeia Drug Discovery, Inc. (Nasdaq:PCOP) today announced that they have entered into a multi-year drug discovery and development alliance. Biovitrum and Pharmacopeia will work together to identify and optimise small molecule lead compounds suitable for advancing into pre-clinical development for multiple targets within the metabolic disease area. Under the terms of this agreement, Biovitrum will access Pharmacopeia's unique drug discovery assets, including its multi-million compound collection of proprietary drug-like small molecules and its drug discovery expertise to identify and optimise leads. The alliance is structured to leverage Biovitrum's biology expertise and considerable domain experience in metabolic diseases. In the true spirit of a strategic alliance, Pharmacopeia will receive some initial funding to offset its research investment but will secure greater part of the return on its investment upon the successful achievement of pre-clinical and clinical milestones. Pharmacopeia will also receive royalties upon the commercialisation of any drugs resulting from the collaboration. Biovitrum will be responsible for development and will retain all marketing rights to collaboration products.
QLogic Introduces Industry's First 4Gb Stackable Switch and Industry's First Software Capable of Installing a Entire SAN in Minutes
ORLANDO, Fla., Oct. 26, 2004 (PRIMEZONE) -- Storage Networking World -- QLogic Corp. (Nasdaq:QLGC), the company that powers storage area networks (SANs), today unveiled an array of innovative new products addressing the application-specific needs of small, medium and large business. Included in the group of new products is SANsurfer Express, the industry's first software capable of installing a SAN in minutes, including HBAs, switches and disk arrays. Also included in the group of new products is the SANbox 5602, the industry's first 4Gb stackable Fibre Channel switch.
BSD Medical Corporation
NYU Cancer Center Features New System by BSD Medical
SALT LAKE CITY, Oct. 26, 2004 (PRIMEZONE) -- BSD Medical Corp. (OTCBB:BSDM) today announced that New York University Clinical Cancer Center has installed a new BSD-500 hyperthermia system produced by BSD Medical, Corp. The recently opened Center, which occupies 85,000 square feet between Lexington and Third Avenues in New York City, includes several multidisciplinary specialties for treatment of such cancers as breast and other female cancers, digestive tract, prostate, brain, lung, blood, head and neck, and skin (melanoma). Many of these cancers are applicable for treatment with the BSD-500.
eLocity Inc. -- Investor Alerts on October 26th, 2004 Issued For: DBTC, CNCT, NVAC, NMKT
SARASOTA, Fla., Oct. 26, 2004 (PRIMEZONE) -- The following is an investment opinion issued by eLocity Inc.: Diabetic Treatment Centers of America, Inc. (OTCBB:DBTC), Connetics Corporation (Nasdaq:CNCT), Nova Communications Ltd. (OTCBB:NVAC) and NewMarket Technology, Inc. (OTCBB:NMKT).
Sagient Research Systems
PlacementTracker Publishes Q3 2004 PIPE Market League Tables
SAN DIEGO, Oct. 26, 2004 (PRIMEZONE) -- Sagient Research Systems (OTCBB:SRYS), a leading publisher of independent research for the financial services and institutional investment communities, today announced that Roth Capital Partners, LLC ranked as the No. 1 investment bank in the PIPE market in the third quarter of 2004 for total number of transactions and that UBS Investment Bank ranked as the No. 1 investment bank in the PIPE market in the third quarter of 2004 for total dollars raised. Laurus Funds topped the list of most active institutional investors during the third quarter of 2004.